Bio-IT World June 23, 2021
In the not-too-distant future, physicians and pharmaceutical companies could have a tool to predict how well a drug will perform in patients and optimize its therapeutic efficacy. The enabler will be “virtual clinical trials”—employing digital representations of patients and running in parallel with actual clinical trials—to understand what separates responders and nonresponders to a drug, according to Himanshu Kaul, D.Phil. (Oxon), research fellow in the Royal Academy of Engineering at the University of Leicester.
Kaul says he is a huge fan of mathematical models that are “agent-based” and therefore capture the heterogeneity of biological systems, including what is happening at the cell and organ levels that contribute to health and disease. In the long run, he is intent on building...
Today's Sponsors
Today's Sponsor